Abstract
In this study we measured S-100B using a recently developed luminometric immunoassay with a detection limit of 0.02 microg l(-1). By measuring serum S-100B concentrations in 58 apparently healthy individuals a reference value of 0.16 microg l(-1) was found. To assess the sensitivity of the assay we measured levels of S-100B protein in the serum of 251 patients with cutaneous malignant melanoma before the start of treatment. Only one of 179 patients with limited disease had a serum concentration higher than the reference value, whereas elevated levels were seen in 79% of patients with metastasized disease. In the latter group the NSE serum concentration was elevated in 42%. Using a receiver operating characteristic (ROC) curve it is shown that S-100B is a significantly better parameter than neuron-specific enolase (NSE) for distinguishing patients with limited disease from those with extensive melanoma. Pretreatment S-100B values were highly predictive for the period of survival. Patients with limited disease have increased risk for early death with increasing levels of S-100B protein. Within the group of patients with positive lymph nodes and/or with distant metastases, elevated S-100B levels strongly identified high-risk patients. Our study indicates that the measurement of S-100B as a tumour marker in the management of patients with cutaneous malignant melanoma has clinical significance.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bonfrer, J., Korse, C., Nieweg, O. et al. The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br J Cancer 77, 2210–2214 (1998). https://doi.org/10.1038/bjc.1998.368
Issue Date:
DOI: https://doi.org/10.1038/bjc.1998.368
This article is cited by
-
PTPRC functions as a prognosis biomarker in the tumor microenvironment of cutaneous melanoma
Scientific Reports (2023)
-
The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy
American Journal of Clinical Dermatology (2016)
-
Is increased serum S-100 protein concentration a marker of metastasis in malignant melanoma? A four-year experience report
European Journal of Plastic Surgery (2005)
-
Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine
Cancer Immunology, Immunotherapy (2003)